• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

S6K1 在 ER 阳性乳腺癌中的作用。

The role of S6K1 in ER-positive breast cancer.

机构信息

Department of Biology, Stern College for Women of Yeshiva University, New York, NY, USA.

出版信息

Cell Cycle. 2012 Sep 1;11(17):3159-65. doi: 10.4161/cc.21194. Epub 2012 Aug 16.

DOI:10.4161/cc.21194
PMID:22895181
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC3466514/
Abstract

The 40S ribosomal S6 kinase 1 (S6K1) is a conserved serine/threonine protein kinase that belongs to the AGC family of protein kinases, which also includes Akt and many others. S6K1 is the principal kinase effector downstream of the mammalian target of rapamycin complex 1 (mTORC1). S6K1 is sensitive to a wide range of signaling inputs, including growth factors, amino acids, energy levels and hypoxia. S6K1 relays these signals to regulate a growing list of substrates and interacting proteins in control of oncogenic processes, such as cell growth and proliferation, cell survival and apoptosis and cell migration and invasion. Several lines of evidence suggest an important role for S6K1 in estrogen receptor (ER)-positive breast cancer. S6K1 directly phosphorylates and activates ERα. Furthermore, S6K1 expression is estrogenically regulated. Therefore, hyperactivation of mTORC1/S6K1 signaling may be closely related to ER-positive status in breast cancer and may be utilized as a marker for prognosis and a therapeutic target.

摘要

40S 核糖体 S6 激酶 1(S6K1)是一种保守的丝氨酸/苏氨酸蛋白激酶,属于蛋白激酶 AGC 家族,该家族还包括 Akt 和许多其他激酶。S6K1 是哺乳动物雷帕霉素靶蛋白复合物 1(mTORC1)下游的主要激酶效应物。S6K1 对多种信号输入敏感,包括生长因子、氨基酸、能量水平和缺氧。S6K1 将这些信号传递下去,以调节细胞生长和增殖、细胞存活和凋亡以及细胞迁移和侵袭等致癌过程中越来越多的底物和相互作用蛋白。有几条证据表明 S6K1 在雌激素受体(ER)阳性乳腺癌中发挥着重要作用。S6K1 直接磷酸化并激活 ERα。此外,S6K1 的表达受雌激素调控。因此,mTORC1/S6K1 信号的过度激活可能与乳腺癌的 ER 阳性状态密切相关,并可能被用作预后标志物和治疗靶点。

相似文献

1
The role of S6K1 in ER-positive breast cancer.S6K1 在 ER 阳性乳腺癌中的作用。
Cell Cycle. 2012 Sep 1;11(17):3159-65. doi: 10.4161/cc.21194. Epub 2012 Aug 16.
2
Trastuzumab stimulation of ribosomal protein S6 kinase 1 (S6K1) predicts de novo trastuzumab resistance.曲妥珠单抗刺激核糖体蛋白S6激酶1(S6K1)可预测曲妥珠单抗的原发性耐药。
Biochem Biophys Res Commun. 2017 Jan 29;483(1):739-744. doi: 10.1016/j.bbrc.2016.12.072. Epub 2016 Dec 18.
3
mTORC1 directly phosphorylates and activates ERα upon estrogen stimulation.在雌激素刺激下,mTORC1直接磷酸化并激活雌激素受体α。
Oncogene. 2016 Jul 7;35(27):3535-43. doi: 10.1038/onc.2015.414. Epub 2015 Nov 2.
4
Cross-talk between sirtuin and mammalian target of rapamycin complex 1 (mTORC1) signaling in the regulation of S6 kinase 1 (S6K1) phosphorylation.Sirtuin 和哺乳动物雷帕霉素靶蛋白复合物 1(mTORC1)信号通路在 S6 激酶 1(S6K1)磷酸化调节中的串扰。
J Biol Chem. 2014 May 9;289(19):13132-41. doi: 10.1074/jbc.M113.520734. Epub 2014 Mar 20.
5
mTORC1-activated S6K1 phosphorylates Rictor on threonine 1135 and regulates mTORC2 signaling.mTORC1 激活的 S6K1 在苏氨酸 1135 上磷酸化 Rictor,并调节 mTORC2 信号。
Mol Cell Biol. 2010 Feb;30(4):908-21. doi: 10.1128/MCB.00601-09. Epub 2009 Dec 7.
6
S6K1 alternative splicing modulates its oncogenic activity and regulates mTORC1.S6K1 选择性剪接调节其致癌活性并调节 mTORC1。
Cell Rep. 2013 Jan 31;3(1):103-15. doi: 10.1016/j.celrep.2012.11.020. Epub 2012 Dec 27.
7
Elevated protein kinase D3 (PKD3) expression supports proliferation of triple-negative breast cancer cells and contributes to mTORC1-S6K1 pathway activation.蛋白激酶 D3(PKD3)表达升高可支持三阴性乳腺癌细胞的增殖,并促进 mTORC1-S6K1 通路的激活。
J Biol Chem. 2014 Feb 7;289(6):3138-47. doi: 10.1074/jbc.M113.502633. Epub 2013 Dec 11.
8
Estrogenic regulation of S6K1 expression creates a positive regulatory loop in control of breast cancer cell proliferation.雌激素对 S6K1 表达的调节在控制乳腺癌细胞增殖中形成了一个正反馈调节环。
Oncogene. 2012 Dec 6;31(49):5073-80. doi: 10.1038/onc.2011.657. Epub 2012 Jan 30.
9
S6 kinase 1 regulates estrogen receptor alpha in control of breast cancer cell proliferation.S6激酶1在控制乳腺癌细胞增殖过程中调节雌激素受体α 。
J Biol Chem. 2009 Mar 6;284(10):6361-9. doi: 10.1074/jbc.M807532200. Epub 2008 Dec 27.
10
The mechanistic target for rapamycin pathway is related to the phosphorylation score for estrogen receptor-α in human breast tumors in vivo.雷帕霉素作用机制靶点通路与人类乳腺肿瘤中雌激素受体-α的磷酸化评分在体内相关。
Breast Cancer Res. 2014 May 22;16(3):R49. doi: 10.1186/bcr3660.

引用本文的文献

1
Lymphangioleiomyomatosis and Pregnancy-Do We Have All the Answers for a Woman Who Desires to Conceive?-Literature Review.淋巴管平滑肌瘤病与妊娠——对于渴望怀孕的女性,我们是否掌握了所有答案?——文献综述
Cancers (Basel). 2025 Jan 20;17(2):323. doi: 10.3390/cancers17020323.
2
Development of 6-amido-4-aminoisoindolyn-1,3-diones as p70S6K1 inhibitors and potential breast cancer therapeutics.6-酰胺基-4-氨基异吲哚啉-1,3-二酮作为p70S6K1抑制剂及潜在乳腺癌治疗药物的研发
Front Mol Biosci. 2024 Dec 19;11:1481912. doi: 10.3389/fmolb.2024.1481912. eCollection 2024.
3
Estrogen Receptor Is Required for Metformin-Induced Apoptosis in Breast Cancer Cells Under Hyperglycemic Conditions.雌激素受体是高血糖条件下二甲双胍诱导乳腺癌细胞凋亡所必需的。
Breast Cancer (Auckl). 2024 Apr 8;18:11782234241240173. doi: 10.1177/11782234241240173. eCollection 2024.
4
A Fecal-Microbial-Extracellular-Vesicles-Based Metabolomics Machine Learning Framework and Biomarker Discovery for Predicting Colorectal Cancer Patients.一种基于粪便微生物细胞外囊泡的代谢组学机器学习框架及用于预测结直肠癌患者的生物标志物发现
Metabolites. 2023 Apr 25;13(5):589. doi: 10.3390/metabo13050589.
5
Identification of Novel Protein Targets of Prodigiosin for Breast Cancer Using Inverse Virtual Screening Methods.采用反向虚拟筛选方法鉴定灵菌红素治疗乳腺癌的新型蛋白靶标。
Appl Biochem Biotechnol. 2023 Dec;195(12):7236-7254. doi: 10.1007/s12010-023-04426-9. Epub 2023 Mar 29.
6
Mechanisms of Resistance to CDK4/6 Inhibitors and Predictive Biomarkers of Response in HR+/HER2-Metastatic Breast Cancer-A Review of the Literature.HR+/HER2-转移性乳腺癌对CDK4/6抑制剂的耐药机制及反应预测生物标志物——文献综述
Diagnostics (Basel). 2023 Mar 5;13(5):987. doi: 10.3390/diagnostics13050987.
7
Guava Leaf Essential Oil as a Potent Antioxidant and Anticancer Agent: Validated through Experimental and Computational Study.番石榴叶精油作为一种有效的抗氧化剂和抗癌剂:通过实验和计算研究验证
Antioxidants (Basel). 2022 Nov 7;11(11):2204. doi: 10.3390/antiox11112204.
8
Development and Validation of a Six-Gene Prognostic Signature for Bladder Cancer.膀胱癌六基因预后特征的开发与验证
Front Genet. 2021 Dec 6;12:758612. doi: 10.3389/fgene.2021.758612. eCollection 2021.
9
Mechanisms of Resistance to PI3K Inhibitors in Cancer: Adaptive Responses, Drug Tolerance and Cellular Plasticity.癌症中对PI3K抑制剂耐药的机制:适应性反应、药物耐受性和细胞可塑性。
Cancers (Basel). 2021 Mar 26;13(7):1538. doi: 10.3390/cancers13071538.
10
The Trinity of cGAS, TLR9, and ALRs Guardians of the Cellular Galaxy Against Host-Derived Self-DNA.cGAS、TLR9 和 ALRs 的三位一体:守护细胞星系对抗源自宿主的自身 DNA。
Front Immunol. 2021 Feb 11;11:624597. doi: 10.3389/fimmu.2020.624597. eCollection 2020.

本文引用的文献

1
Estrogenic regulation of S6K1 expression creates a positive regulatory loop in control of breast cancer cell proliferation.雌激素对 S6K1 表达的调节在控制乳腺癌细胞增殖中形成了一个正反馈调节环。
Oncogene. 2012 Dec 6;31(49):5073-80. doi: 10.1038/onc.2011.657. Epub 2012 Jan 30.
2
Understanding the mechanisms of aromatase inhibitor resistance.了解芳香化酶抑制剂耐药的机制。
Breast Cancer Res. 2012 Jan 19;14(1):201. doi: 10.1186/bcr2931.
3
Phase II trial of temsirolimus in patients with metastatic breast cancer.替西罗莫司治疗转移性乳腺癌患者的 II 期临床试验。
Breast Cancer Res Treat. 2012 Nov;136(2):355-63. doi: 10.1007/s10549-011-1910-7. Epub 2012 Jan 13.
4
Everolimus in postmenopausal hormone-receptor-positive advanced breast cancer.依维莫司用于绝经后激素受体阳性的晚期乳腺癌。
N Engl J Med. 2012 Feb 9;366(6):520-9. doi: 10.1056/NEJMoa1109653. Epub 2011 Dec 7.
5
Glycogen synthase kinase (GSK)-3 promotes p70 ribosomal protein S6 kinase (p70S6K) activity and cell proliferation.糖原合酶激酶(GSK)-3 促进 p70 核糖体蛋白 S6 激酶(p70S6K)的活性和细胞增殖。
Proc Natl Acad Sci U S A. 2011 Nov 22;108(47):E1204-13. doi: 10.1073/pnas.1110195108. Epub 2011 Nov 7.
6
Phosphatidylinositol 3-kinase and antiestrogen resistance in breast cancer.磷脂酰肌醇 3-激酶与乳腺癌的抗雌激素耐药性。
J Clin Oncol. 2011 Nov 20;29(33):4452-61. doi: 10.1200/JCO.2010.34.4879. Epub 2011 Oct 17.
7
A kinome-wide screen identifies the insulin/IGF-I receptor pathway as a mechanism of escape from hormone dependence in breast cancer.全激酶组筛选鉴定出胰岛素/IGF-I 受体通路是乳腺癌激素依赖逃逸的一种机制。
Cancer Res. 2011 Nov 1;71(21):6773-84. doi: 10.1158/0008-5472.CAN-11-1295. Epub 2011 Sep 9.
8
Involvement of Akt-1 and mTOR in sensitivity of breast cancer to targeted therapy.Akt-1和mTOR在乳腺癌对靶向治疗敏感性中的作用
Oncotarget. 2011 Jul;2(7):538-50. doi: 10.18632/oncotarget.302.
9
mTOR inhibition in breast cancer: unraveling the complex mechanisms of mTOR signal transduction and its clinical implications in therapy.mTOR 抑制在乳腺癌中的作用:揭示 mTOR 信号转导的复杂机制及其在治疗中的临床意义。
Expert Opin Ther Targets. 2011 Jul;15(7):859-72. doi: 10.1517/14728222.2011.575362. Epub 2011 Apr 8.
10
Transcriptional consequences of genomic structural aberrations in breast cancer.乳腺癌基因组结构异常的转录后果。
Genome Res. 2011 May;21(5):676-87. doi: 10.1101/gr.113225.110. Epub 2011 Apr 5.